LDH as a Biochemical Biomarker to Predict Organ Failure in the Emergency Department Setting

NCT01937676 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1250

Last updated 2016-09-07

No results posted yet for this study

Summary

The purpose of this study is evaluate if K3, a novel biomarker, sampled at arrival to the emergency department can be used to predict the development of organ failure measured as SOFA score. K3 consists of lactate dehydrogenase, albumin and magnesium combined.

Conditions

  • Multiple Organ Failure

Sponsors & Collaborators

Principal Investigators

  • Mathias Karlsson, MD, PhD · Karolinska

  • Jan Wernerman, MD, Prof · Karolinska

  • Lars Wiklund, MD, Prof · Uppsala University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2014-04-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01937676 on ClinicalTrials.gov